Semaglutide is a derivative of the naturally occurring GLP-1, a peptide that has been shown to lower blood sugar levels and enhance insulin secretion.

Research shows that Semaglutide may also improve heart, liver, and lung function while helping to slow or prevent the effects of Alzheimer’s disease. It can significantly decrease appetite by delaying gastric emptying and reducing intestinal motility.

Glucagon-Like Peptide-1 (GLP-1) Analogs have been shown to stimulate insulin and suppress glucagon secretion in a glucose-dependent manner.

Retatrutide is a GGG tri-agonist that targets GLP-1 and GIP receptors, akin to standard GLP-1 agonists, but also uniquely activates the glucagon receptor.

This extra receptor interaction enhances glucagon production, leading to the breakdown of stored fats and glycogen, thereby increasing basal metabolism for more consistent fat loss.

Its actions on GLP-1 and GIP receptors promote delayed gastric emptying and appetite control, offering a comprehensive approach to obesity research distinct from older GLP-1 agonists. Further research is required.

Tirzepatide is a synthetic derivative of gastric inhibitory polypeptide (GIP), possessing dual functionality as a glucagon-like peptide-1 (GLP-1) analog.

This unique combination equips GLP-2 with a multifaceted approach to managing metabolic health. GLP-2 showcases its effectiveness in lowering blood glucose levels, enhancing insulin sensitivity, inducing feelings of satiety, and promoting weight loss.

The synergistic action of GIP and GLP-1 receptors activation contributes to its comprehensive impact on metabolic pathways.